1. Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark.
- Author
-
Nielsen KF, Nielsen LB, Dalby T, Lomholt FK, Slotved HC, Fuursted K, Harboe ZB, Jørgensen CS, and Valentiner-Branth P
- Subjects
- Humans, Denmark epidemiology, Female, Aged, Male, Follow-Up Studies, Aged, 80 and over, Vaccine Efficacy, Vaccination, Pneumococcal Vaccines immunology, Pneumococcal Vaccines administration & dosage, Pneumococcal Infections prevention & control, Pneumococcal Infections epidemiology, Pneumococcal Infections microbiology, Pneumococcal Infections immunology, Serogroup, Streptococcus pneumoniae immunology, Streptococcus pneumoniae classification
- Abstract
As a follow-up to a previous study, we investigated vaccine effectiveness (VE) of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against invasive pneumococcal disease (IPD) among 1,254,498 persons >65 years of age as part of a vaccination program in Denmark during April 2020-January 2023. We assessed VE by using a Cox regression model and adjusted for age, sex, and underlying conditions. Using nationwide data, we estimated a VE of PPSV23 against all-type IPD of 32% and against PPSV23-serotype IPD of 41%. Because this follow-up study had more statistical power than the original study, we also estimated VE against IPD caused by PPSV23-serotypes excluding serotype 3; serotype 3; serotype 8; serotype 22F; PPSV23 non-PCV15 serotypes; PPSV23 non-PCV20 serotypes; and IPD over time. Our findings suggest PPSV23 vaccination can protect persons >65 years of age against IPD caused by all serotypes or serotype groupings, except serotype 3.
- Published
- 2024
- Full Text
- View/download PDF